Down to the bitter end.
"The daintiest last, to make the end most sweet," comes to us from Shakespeare’s Richard II, but in the most recent edition of Blood, the paper from Martinez-Lopez et al suggests that by using minimal residual disease (MRD) testing by sequencing, we may be nearing the "end most sweet" or, in 21st century vernacular, the cure of myeloma.
EMORY UNIVERSITY SCHOOL OF MEDICINE.
Sagar
S
Lonial
EMORY UNIVERSITY SCHOOL OF MEDICINE.
Charise
C
Gleason
D005260:Female; D059014:High-Throughput Nucleotide Sequencing; D006801:Humans; D008297:Male; D009101:Multiple Myeloma / Q000175:diagnosis* / Q000235:genetics*